Evidence map›Paper›PMID 21562125›Full record

Trial reportAmerican journal of respiratory and critical care medicine2011

Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury.

National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Michael A Matthay, Roy G Brower, Shannon Carson, Ivor S Douglas, Mark Eisner, Duncan Hite, Steven Holets, Richard H Kallet, Kathleen D Liu and 5 more

Abstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 236 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
236citing papers in PubMed, 14 pooled it
36.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

236 citing papers in PubMed, 14 syntheses or guidelines pooled it, 450 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Between-trial heterogeneity in ARDS research.Intensive care medicine · 2021
    Pooled it
  7. Pharmacological agents for adults with acute respiratory distress syndrome.The Cochrane database of systematic reviews · 2019
    Pooled it
  8. Guideline
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Pooled it
  13. Guideline
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

176 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network
Michael A Matthay
Roy G Brower
Shannon Carson
Ivor S Douglas
Mark Eisner
Duncan Hite
Steven Holets
Richard H Kallet
Kathleen D Liu
Neil MacIntyre
Marc Moss
David Schoenfeld
Jay Steingrub
B Taylor Thompson

Funding

NHLBI NIH HHS N01 HR056165NHLBI NIH HHS N01-HR-56165-56713
6 · The paper itself

Abstract

rationaleβ₂-Adrenergic receptor agonists accelerate resolution of pulmonary edema in experimental and clinical studies.

objectivesThis clinical trial was designed to test the hypothesis that an aerosolized β₂-agonist, albuterol, would improve clinical outcomes in patients with acute lung injury (ALI).

methodsWe conducted a multicenter, randomized, placebo-controlled clinical trial in which 282 patients with ALI receiving mechanical ventilation were randomized to receive aerosolized albuterol (5 mg) or saline placebo every 4 hours for up to 10 days. The primary outcome variable for the trial was ventilator-free days. MEASUREMENTS AND MAIN

resultsVentilator-free days were not significantly different between the albuterol and placebo groups (means of 14.4 and 16.6 d, respectively; 95% confidence interval for the difference, -4.7 to 0.3 d; P = 0.087). Rates of death before hospital discharge were not significantly different between the albuterol and placebo groups (23.0 and 17.7%, respectively; 95%confidence interval for the difference,-4.0 to 14.7%;P = 0.30). In the subset of patients with shock before randomization, the number of ventilator-free days was lower with albuterol, although mortality was not different. Overall, heart rates were significantly higher in the albuterol group by approximately 4 beats/minute in the first 2 days after randomization, but rates of new atrial fibrillation (10% in both groups) and other cardiac dysrhythmias were not significantly different.

conclusionsThese results suggest that aerosolized albuterol does not improve clinical outcomes in patients with ALI. Routine use of β₂-agonist therapy in mechanically ventilated patients with ALI cannot be recommended. Clinical trial registered with www.clinicaltrials.gov (NCT 00434993).

Indexed as

Acute Lung InjuryAdministration, InhalationAdrenergic beta-2 Receptor AgonistsAlbuterolDisease-Free SurvivalDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansMaleMiddle AgedRespiration, ArtificialRetrospective StudiesAdrenergic beta-2 Receptor AgonistsAlbuterol

Identifiers

PMID21562125
PMCPMC3175548
OpenAlexW2102501066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.